Clinical Trials Using Alemtuzumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Alemtuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • Cyclophosphamide and Alemtuzumab in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of cyclophosphamide and alemtuzumab in treating patients with non-Hodgkin lymphoma that have come back or do not respond to treatment. Drugs used in chemotherapy, such as cyclophosphamide and alemtuzumab, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 2 locations

  • Alemtuzumab or Tocilizumab in Combination with Etoposide and Dexamethasone in Treating Patients with Hemophagocytic Lymphohistiocytosis

    This phase II trial studies how well alemtuzumab or tocilizumab in combination with etoposide and dexamethasone work in treating patients with hemophagocytic lymphohistiocytosis. Hemophagocytic lymphohistiocytosis is a disorder that causes abnormal over activity of the immune system. Immunosuppressive therapy, using drugs such as alemtuzumab, tocilizumab, etoposide, and dexamethasone, may decrease the body’s immune system activity and prevent the immune system from causing damage to organs.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia

    This phase II trial studies the safety and efficacy of a nonmyeloablative (bone marrow will not be completely destroyed) donor stem cell transplant in treating patients with congenital (condition or trait present at birth) anemias including sickle cell disease and thalassemia. Giving low doses of total-body irradiation before a donor stem cell transplant may help stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapies, such as alemtuzumab and sirolimus, before transplant may stop this from happening.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies Who Have Undergone Donor Stem Cell Transplant

    In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, researchers would like to specially treat the donor's blood cells to remove cells that are most likely to attack patients' tissues. This will occur in combination with intense conditioning treatment that patients will receive before having a transplant.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases

    This research study will help researchers learn if adding Campath 1H (alemtuzumab) to the low dose chemotherapy patients get before the transplant will decrease the known side effects from an allogeneic stem cell transplantation and provide a treatment for patients with blood disorders or kidney cancer.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Alemtuzumab and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia

    This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, may interfere with the ability of cancer cells to grow and spread.
    Location: See Clinical Trials.gov

  • Recombinant Human Interleukin-15 and Alemtuzumab in Treating Patients with Refractory or Relapsed Chronic or Acute Adult T-Cell Leukemia

    This phase I trial studies the side effects and best dose of recombinant human interleukin-15 when given together with alemtuzumab in treating patients with chronic or acute adult T-cell leukemia which has come back (recurrent). Interleukins, such as recombinant human interleukin-15, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Monoclonal antibodies, such as alemtuzumab, interfere with the ability of cancer cells to grow and spread. Giving recombinant human interleukin-15 and alemtuzumab may work better in treating patients with chronic or acute adult T-cell leukemia.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland